Engineered EVs equipped with surface proteins, such as anti-HER2 or anti-epidermal growth factor receptor (EGFR) antibodies, exhibit significantly improved tumor-targeting capabilities, positioning EVs as versatile platforms for addressing therapeutic resistance and advancing precision oncology [143]. This evidence concerns the gene ERBB2 and neoplasm.